TP53 and neoplasm: The PBT24 control tumor had lower PCNA and EZH2 expression than the SF8628 tumor, while p53 and survivin expression did not differ between the tested tumors on the CAM; the 10 mM of DCA-containing preparations significantly reduced EZH2 expression in the SF8628 and PBT24 tumors, abolishing this difference between the PBT24 and SF8628 tumors.